Infigratinib is a selective FGFR1-3 inhibitor; it showed an ORR of 23.1% in 108 patients with previously-treated, unresectable locally advanced or metastatic, FGFR2 fusion/rearrangement-positive cholangiocarcinoma (CCA) in a single-arm, phase II study [13, 14] and received US FDA approval for this indication in 2021. Here, FGFR2 is linked to cholangiocarcinoma.